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Background: Magnetic resonance imaging (MRI) plays an irreplaceable role in the preoperative diagnosis of
glioma, and its imaging features are the base of making treatment decisions in patients with glioma, but it is still
controversial whether peritumoral edema shown by MRI from preoperative routine scans are associated with
patient survival. The aim of this study was to assess the prognostic value of preoperative MRI features in patients
with glioblastoma.
Methods: A retrospective review of 87 patients with newly diagnosed supratentorial glioblastoma was performed
using medical records and MRI data from routine scans. The Kaplan-Meier method and COX proportional hazard
model were applied to evaluate the prognostic impact on overall survival of pretreatment MRI features (including
peritumoral edema, edema shape, necrosis, cyst, enhancement, tumor crosses midline, edema crosses midline, and
tumor size).
Results: In addition to patient age, Karnofsky performance status (KPS) and postoperative chemoradiotherapy,
peritumoral edema extent and necrosis on preoperative MRI were independent prognostic indicator for poor
survival. Furthermore, patients with two unfavorable conditions (major edema and necrosis) had a shorter overall
survival compared with the remainder.
Conclusions: Our data confirm that peritumoral edema extent and necrosis are helpful for predicting poor clinical
outcome in glioblastoma. These features were easy to determine from routine MRI scans postoperatively and
therefore could provide a certain instructive significance for clinical activities.
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Glioblastoma multiforme (GBM) is the most prevalent
malignant brain tumor in adults and accounts for 17% of
intracranial tumors [1]. To date, effective durable treat-
ments in patients with GBM are still lacking, exhibiting
a poor prognosis with a median overall survival rate of
9.4 to 19.0 months despite advances in multimodal
treatments that combine surgery, radiation therapy, and
chemotherapy [2].
Magnetic resonance imaging (MRI) technology is a
common and noninvasive diagnostic modality and was
previously found to take examination in central nervous* Correspondence: Lzx1967@sina.com
†Equal contributors
1Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical
University, Beijing 100093, China
2Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
University, 20 Cazhong Road, Fuzhou, Fujian 350005, China
© 2015 Wu et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.system disease in clinical and especially in the preoperative
diagnosis of glioma. Moreover, MRI is not only a powerful
tool to visualize changes in morphological abnormalities
but also a direct reflection of biochemical changes in the
tumor and surrounding tissue. MRI can have great utility
in the diagnosis, grading, and management of patients with
GBM as many of the physical manifestations of the patho-
logic processes in GBM can be visualized and quantified
using MRI. Better taking account of the correlation be-
tween preoperative tumor imaging features and survival is
therefore useful to clinic.
For patients with GBM, clinical data-including age, peri-
operative Karnofsky performance status (KPS), pathological
molecular markers, tumor resection, adjuvant radiochemo-
therapy, and tumor imaging features (including necrosis
and edema) have been found to correlate with survival
[3-7]. Moreover, a clear relationship among survival patternis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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established. Some tumor imaging features of preoperative
MRI from conventional scans, such as peritumoral edema
(PTE) extent, necrosis, enhancement, and the size of cyst,
were considered to be correlated with patient survival.
[5,8-11]. However, several reports showed that these fea-
tures, such as PTE and necrosis, were not independent
values of survival in patients with glioblastoma [12-17].
These controversial results therefore suggest that there
remains a need to further evaluate whether PTE and ne-
crosis on MRI are associated with patient survival because
such data from routine imaging play an irreplaceable role
during preoperative diagnosis and now are the kernel
base of making treatment decisions in patients with gli-
oma, clearly recognizing the relationship among them has
a certain instructive significance for clinical practice.
Here, the tumor imaging features (including PTE, edema
shape, necrosis, cyst, enhancement, tumor crosses mid-
line, edema crosses midline, and tumor size) from pre-
operative routine MRI scans were assessed, and the aim of
our study was to examine whether these characters are




Clinical and preoperative MRI data of 87 patients treated
with resection of newly diagnosed supratentorial GBM
at Beijing Sanbo Brain Hospital of Capital Medical
University between April 2009 and March 2013 were
introduced into this retrospective study. The exclusion
criteria in this study were as follows: i) patients who died
of non-glioma cause, ii) patients who received biopsy
were excluded from the study, ii) patients who received
Corticosteroids at the time of the preoperative MRI
scan. For all patients enrolled in the study, the tumor
was confirmed to be totally resected using postoperative
enhanced MRI within 3 days. According to the principles
of WHO classification [1], the histological diagnosis of
each patient was reaffirmed. Postoperatively, radiotherapy
(plus concurrent temozolomide chemotherapy at a dose
of 75 mg/M2/day) was administered in contrast-enhanced
lesion plus the area of PTE and a 2-cm margin (60 Gy in
2 Gy fractions). Then, temozolomide chemotherapy (150
to 200 mg/M2/day) was administered for six cycles
unless death or irreversible hematological toxicity oc-
curred. All patients were followed up through either
telephone or outpatient visit. Overall survival (OS) was
defined as the time interval (days) between primary
surgical resection and death (or the latest follow-up).
This study was approved by the local Ethics Committee
and was conformed to the principles outlined in Declar-
ation of Helsinki. Written informed consent was provided
by all patients.Classification of MRI features
For all patients, preoperative MRI data from routine scans
(1.5-T scanner) including T1-W, T2-W, and contrast-
enhanced T1-W sequences were available. The unidimen-
sional maximum diameter in centimeters was used for
measuring tumor size on T1-W images; median tumor
size was 5.0 cm (rang 2.3 to 9.9 cm). The region of very
bright T2-W signal surrounding the tumor was defined as
PTE, which was estimated on the base of the maximum
distance from the tumor margin to the outer edge of
edema and was graded as follows [6]: minor (Figure 1A)
and major (Figure 1B). According to the method of
Hartmann [18], the morphological classification of PTE
was performed on the base of T2-W images. Necrosis
which was estimated on axial contrast-enhanced T1-W
images [19] was determined when a region had high signal
on T2-W images, but low signal on T1-W images, and
had an irregular enhancing border on contrast-enhanced
images. Cyst was defined as a rounded region which was
low T1-W signal and very high T2-W signal matching
cerebrospinal fluid (CSF) signal and had a thin, smooth,
regular, and slightly enhancing or non-enhancing wall
[10]. Contrast enhancement in tumor was grouped as no
obvious (enhancement signal is less than the signal of fat)
and obvious (enhancement signal is similar to that of fat).
The specific classification of imaging features was listed
in Table 1. According to the classification methods men-
tioned above, imaging data of all patients were analyzed
independently by two experienced radiologists without
knowledge of patient clinical information.
Statistical analysis
SPSS 19.0 was applied to statistical analysis. In univariate
analysis, the Kaplan-Meier method was used to calculate
survival rates which were compared by the log-rank test.
COX proportional hazard model and stepwise regression
analysis were applied to estimate the influence of pre-
operative MRI features on survival in multivariate analysis.
Hazard ratios (HRs) and their 95% confidence intervals




Out of 87 cases, 55 (63.2%) patients were male and 32
(63.2%) were female. Median age at diagnosis was 60 years
(range 25 to 78). Median preoperative KPS of patients was
80 (range 70 to 100). Postoperatively, forty-three patients
were treated with radiotherapy plus chemotherapy, which
was determined as standard chemoradiotherapy; twenty-
nine patients had radiotherapy; eleven patients had chemo-
therapy alone; and four patients refused radiotherapy and
chemotherapy. For statistical analysis, these patients were
defined as nonstandard chemoradiotherapy.
Table 1 Specific classification of MRI features
Imaging features Classification criterion
Edema extent
Minor Peritumoral edema extending <1 cm from tumor margin
Major Peritumoral edema extending ≥1 cm from tumor margin
Edema shape
Roundish The shape of edema is similar to round and is not radial
Irregular The shape of edema tends to irregular, such as finger-like or radial shape
Necrosis
No No necrosis within tumor
Yes A region had high signal on T2-W images, but low signal on T1-W images,
and had an irregular enhancing border on contrast-enhanced images
Cyst
No No cyst in tumor
Yes A rounded region which was very low T1-W signal and very high T2-W signal matching cerebrospinal
fluid signal, and had a thin, smooth, regular, and slightly enhancing or non-enhancing wall
Enhancement
No obvious Enhancement signal is less than the signal of fat
Obvious Enhancement signal is similar to that of fat
Tumor crosses midline
No Tumor is limited to unilateral cerebral hemisphere
Yes Tumor crosses the brain midline and extends into the other side of cerebral hemisphere
Edema crosses midline
No Peritumoral edema extent is limited to unilateral cerebral hemisphere
Yes Peritumoral edema extent crosses the brain midline and is not confined to unilateral cerebral hemisphere
Size (cm)
<5 The maximum diameter of tumor is less than 5 cm
≥5 The maximum diameter of tumor is equal to or more than 5 cm
Figure 1 Eveluation of PTE. A region of very bright T2-W signal surrounding the tumor, which was estimated on the base of the maximum distance
from the tumor margin to the outer edge of edema. (A) Minor edema (<1 cm) shown by T2-W MRI. (B) Major edema (>1 cm) shown by T2-W MRI.
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subgroups is summarized in Table 2. A statistically sig-
nificant correlation emerged among edema extent with
edema shape (R = 0.570, P = 0.000) and enhancement
(R = 0.436, P = 0.000). No significant correlation was found
between edema grade and gender, age, KPS, necrosis,
cyst, tumor crosses midline, edema crosses midline, and
tumor size.
Survival analysis
To evaluate the influence of on prognosis, telephone or

































≥5 50 (57.5)up time minimum 101 days, maximum 1,198 days, me-
dian 352 days), and corresponding OS was calculated. Out
of 87 patients, the median OS was 435 days (95% CI 374
to 495) in the entire cohort. Univariate analysis (Table 3)
revealed major PTE was shown to be significantly associ-
ated with a dismal OS (P = 0.019, Figure 2A) and patients
with minor PTE exhibited longer survival compared with
major edema. Additionally, similar results were obtained
for edema shape (P = 0.007, Figure 2B), necrosis (P = 0.000,
Figure 2C), enhancement (P = 0.003, Figure 2D), patient
age (P = 0.001, Figure 2E), KPS (P = 0.005, Figure 2F), and
chemoradiotherapy (P = 0.013, Figure 2G). However, nooral edema subgroup
Peritumoral edema extent
Minor edema (%) Major edema (%)
19 (21.8) 68 (78.2)
14 (73.7) 41 (60.3)
5 (26.3) 27 (39.7)
12 (63.2) 38 (55.9)
7 (36.8) 30 (44.1)
5 (26.3) 28 (41.2)
14 (73.7) 40 (58.8)
16 (84.2) 13 (19.1)
3 (15.8) 55 (80.9)
6 (31.6) 10 (14.7)
13 (68.4) 58 (85.3)
15 (78.9) 52 (75.4)
4 (21.1) 16 (24.6)
14 (73.7) 16 (23.5)
5 (26.3) 52 (76.5)
17 (89.5) 54 (79.4)
2 (10.5) 14 (20.6)
17 (89.5) 42 (61.8)
2 (10.5) 26 (38.2)
6 (31.6) 31 (45.6)
13 (68.4) 37 (54.4)
Table 3 Variables associated with the overall survival in the entire cohort: univariate analysis
Variables Number of cases Overall survival (days) P-value
Median 95% CI
Total 87 435 374 to 495
Gender
Male 55 437 372 to 501 0.723
Female 32 423 362 to 484
Age (years)
≥60 50 321 166 to 473 0.001
<60 37 504 327 to 681
KPS
≤80 33 321 187 to 455 0.005
>80 54 504 323 to 684
Chemoradiotherapy
Standard 43 498 369 to 627 0.013
Nonstandard 44 352 229 to 474
Edema extent
Minor 19 599 397 to 956 0.019
Major 68 411 332 to 489
Edema shape
Roundish 29 591 270 to 962 0.007
Irregular 58 411 283 to 539
Necrosis
No 16 687 476 to 856 0.000
Yes 71 410 311 to 510
Cyst
No 67 436 382 to 490 0.73
Yes 20 391 206 to 575
Enhancement
No obvious 30 573 412 to 734 0.003
Obvious 57 391 275 to 507
Tumor crosses midline
No 71 436 382 to 490 0.73
Yes 16 391 206 to 575
Edema crosses midline
No 59 458 417 to 498 0.153
Yes 28 321 212 to 430
Size (cm)
<5 37 391 226 to 527 0.305
≥5 50 458 263 to 652
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cyst, tumor crosses midline, edema crosses midline, and
tumor size (P > 0.05).
Factors which were statistically significant from univar-
iate analysis were introduced into multivariate analysis.
Multivariate survival analysis (Table 4) demonstrated majoredema and necrosis on MRI as significant prognostic indi-
cators for shorter OS (HR 2.274, P = 0.015; HR 2.215, P =
0.001, respectively). Likewise, advanced age at diagnosis
(≥60 years), poor performance status (≤80), and non-
standard chemoradiotherapy were also confirmed to be
independent predictors for poor OS.
Figure 2 Kaplan-Meier curves. Kaplan-Meier curves showing correlations of PTE (A), edema shape (B), enhancement necrosis (C), enhancement
(D), age (E), KPS (F), chemoradiotherapy (G), and major PTE and necrosis (H) with overall survival in the entire cohort.
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patients with two unfavorable factors (major edema and
necrosis) had a shorter survival compared with thosewith only one or without unfavorable factor (either major
edema or necrosis). The statistical results revealed that
the prognosis in patients with two unfavorable factors was
Table 4 Statistically significant prognosis indicators
evaluated by multivariate analysis in the entire cohort
Variables Hazard ratio (HR) 95% CI P-value
Edema extent 2.274 1.238 to 5.991 0.015
Necrosis 2.215 1.447 to 3.401 0.001
Age 1.954 1.137 to 3.358 0.029
KPS 0.502 0.292 to 0.864 0.013
Chemoradiotherapy 0.358 0.204 to 0.630 0.000
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When adjusted for patient age, KPS, and chemoradiother-
apy and the adjusted HR was 1.0 (as a reference), the ad-
justed HR of patients with two unfavorable factors was
5.031 (95% CI 2.449 to 10.338, P = 0.000) for OS.
Discussion
While the prognosis for patients with GBM is relatively
poor, variability of survival among patients who are given
the same malignant level suggests that there are additional
underlying factors that influence how the tumor pro-
gresses. The main causes of morbidity and mortality in gli-
oma patients is the induction of severe cerebral edema
and necrosis, which lead to brain herniation in up to 60%
of patients with GBM [20], but some study suggested that
there is still a controversy about these prognostic values
[15,16,18]. Therefore, the relationship between survival
and the appearance of tumor on MRI is important. In our
retrospective study, we found that PTE and necrosis were
statistically significant unfavorable prognosis factors af-
fecting OS in patients with newly diagnosed supratentorial
GBM.
PTE, the abnormal accumulation of water inside the
brain parenchyma, is commonly seen in GBM patients
[16]. Our study found that edema was significant prog-
nostically in both univariate and multivariable analysis,
as others have reported. Patients with minor PTE exhib-
ited longer survival compared with major edema. Multi-
variate survival analysis demonstrated major edema on
MRI as independent prognostic indicators for shorter
OS (HR 2.274, P = 0.015, respectively). Based on the lit-
erature, we hypothesized that it may be related to the
fact that the tumor cells infiltrate the peritumoral-edema
areas [21]. Second off, glioblastoma is associated with
infiltration of peritumoral parenchyma by isolated tumor
cells that leads to tumor regrowth. Recently, GBM stem-
like or initiating cells (GICs) have been identified in the
peritumoral areas [22], and these GICs have enhanced
migratory and invasive capabilities compared with GICs
from the tumor mass, which are the sources of tumor
recurrence [23-25]. Moreover, peri-tumoral edematous
fluid can accumulate rapidly in severe cases [26]. Within
the rigid skull, rapid augmentation of brain volume leads
to a sharp increase in ICP, which can result in decreasedcerebral blood flow, ischemia, brain herniation, and death
[26]. In this study, the extent of edema turned out to be
an independent prognostic factor in patients with GBM,
which confirms the results of Pope WB and K Schoenegger.
However, in the literature, results concerning the prognos-
tic impact of brain edema in glioblastoma patients have
not been conclusive and uniform. Other studies either
found that there was no relationship between these vari-
ables [10,12,14] or that the relationship varied depending
on the extent of the edema [11]. Many remarkable factors
contribute to the explanations, firstly, given the nature of
the studies included was retrospective and the between-
study heterogeneity in terms of patient clinical charac-
teristics and the imaging technology used about the
topic, another factor which was inconsistent among
these studies in evaluation and definition of PTE [15].
Our study also showed that a statistically significant cor-
relation emerged among edema extent with edema shape
(R = 0.570, P = 0.000) and enhancement (R = 0.436, P =
0.000); the patients with irregular shape of edema and ob-
vious enhancement survived shorter than those with vice
versa, but multivariate analysis indicated that edema shape
and enhancement were both not an independent predictor
of prognosis. It is thought that blood–brain barrier break
downs and typically lacks endothelial tight junctions
in GBM, which leads to both enhancement and edema.
In addition, the perifocal edema is proposed as the clinical
target volume, since it has been supposed to contain
infiltrating tumor cells, which spread to white matter
fiber, causing the irregular shape of edema (such as radial
or finger-like shape), both ultimately influences patient
survival.
Necrosis is one of the radiologic and pathological
characteristics of glioblastoma; in particular, the absence
of necrosis on imaging studies was an important prog-
nostically favorable variety, confirming the findings of
Hammoud et al. Necrotic areas within a glioma are a com-
mon imaging feature and are believed to indicate rapid
growth and malignant behavior. Previous studies have con-
flicted that tumor necrosis was related to survival in GBM
[9,26,27]. In a series of 75 glioblastoma patients, David A.
Gutman et al. found contrast-enhanced tumor volume and
longest axis length of tumor were strongly associated with
poor survival. While necrosis was not found to be an inde-
pendent prognostic factor [28].In the present study, necro-
sis on preoperative MRI was found to be an independent
prognostic factor in multivariate analysis (HR 2.215, P =
0.001, respectively). One proposed explanation is that the
rapid cellular proliferation of tumor cells brings about nu-
trient unbalance, which leads to hypoxia and until necrosis
in tumor tissue. Hypoxia selects for cells with diminished
apoptotic potential relative to those in the original cell
population. Moreover, necrosis and hypoxia in gliomas
lead to upregulation of vascular endothelial growth factor
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making the tumor cell population peripheral to the necro-
sis, improving the invasion ability and resistance to radio-
chemotherapy [31-35].
Previous studies showed that enhancement on pre-
operative contrast T1-weight MRI was an independent
value of survival in GBM [9,25]. However, in this study,
enhancement was related to OS of GBM in univariate
analysis while not same in multivariate analysis. According
to the hypothesized pathways that are present in the study,
the enhancement of tumors mainly reflects the destruc-
tion of blood–brain barrier maintenance and is influenced
by all processes that decrease or increase the abnormal
permeability, in spite of the size and activity of tumor [36].
It was previously thought that cysts were associated with
improved outcome [37-39]. It is probably that the etiology
of cyst formation implies more indolent tumor growth
[13]. Nevertheless, our study demonstrates that the pres-
ence of cystic features does not confer a survival advan-
tage, which is in accordance with a recent large-series
study [13]. However, the exact mechanism of cyst forma-
tion remains unclear and needed to be further researched.
In addition to the clinical characteristics of age and pre-
operative KPS score, for which the relationship to survival
is well established [4,5], we observed the same results in
our series, advanced age at diagnosis (≥60 years), poor per-
formance status (≤80), and nonstandard chemoradiother-
apy were also confirmed to be independent predictors for
poor OS (HR 1.954, P = 0.029; HR 0.502, P = 0.029, respect-
ively). We deduce that it might be due to the biological
characteristics and behaviors of glioma cells of patient at
different age group. Moreover in our study, postoperative
standard radio-chemotherapy could prolong the survival
time for patients with GBM (HR 0.358, P = 0.000, respect-
ively), which is in accordance with previous studies [3,40];
thus, it is advocated actively to take standard therapy regi-
men for patients with GBM postoperatively.
However, it should be noted that in this study, many in-
herently limitations exist. Obviously, this is a retrospective-
design research which might be inevitably subject to bias
that not all can be controlled for in this context. Further-
more, limitations of the study include small sample size.
In the future, to further disclose the key molecular mecha-
nisms of those independent predictors of survival, large-
scale and prospective studies are needed.
Conclusions
In summary, PTE extent and necrosis shown by MRI from
preoperative routine scans are independent unfavorable
prognosis indicators, and a patient with both major edema
and necrosis exhibits a poorer prognosis, thereby indicat-
ing that PTE extent and necrosis which are easy to be de-
termined from routine MRI scans can be used to predict
OS in patients with newly diagnosed GBM.Abbreviations
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